ERBB2 and breast cancer: In breast cancer, ClpP activation sensitizes cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and enhances apoptotic signaling, particularly in HER2+ subtypes [27].